Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET
Company Participants
Arthur Stril - Interim Chief Financial Officer
Andre Choulika - Chief Executive Officer
Adrian Kilcoyne - Chief Medical Officer
Conference Call Participants
Gena Wang - Barclays
Jack Allen - Baird
Ashiq Mubarack - Citi
Kuan-Hung Lin - Wells Fargo
Luisa Morgado - Van Lanschot Kempen
Silvan Tuerkcan - Citizens JMP
Operator
Good morning, everyone, and welcome to the Cellectis Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. Please be aware that today's conference call is being recorded.
I would now like to introduce the first speaker, Arthur Stril, Chief Financial Officer. You may begin.
Arthur Stril
Good morning, and welcome, everyone, to Cellectis Third Quarter 2024 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer; and Dr. Adrian Kilcoyne, our Chief Medical Officer.
Yesterday evening, Cellectis issued a 6-K and press release reporting our financial statements for the nine months period ended September 30th, 2024, and a business update. The report and press release are available on our website at cellectis.com.
As a reminder, we will make statements regarding Cellectis financial outlook, including the sufficiency of cash to fund operations in addition to its manufacturing, regulatory and product development status as well as product development status of its license partners.
These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our license partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange Commission, SEC, and the financial report, including the management report, for the year ended on December 31st, 2023, and subsequent filings Cellectis makes with the SEC from time to time.
I would now like to turn the call over to Andre.
Andre Choulika
Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. This quarter, we're excited to announce that research and development activities have started for three programs developed under our collaboration and research agreement with AstraZeneca: one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors and one in vivo gene therapy for genetic disorder.